Share This Page
Suppliers and packagers for MICONAZOLE 7
✉ Email this page to a colleague
MICONAZOLE 7
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| P And L | MICONAZOLE 7 | miconazole nitrate | CREAM;VAGINAL | 074164 | ANDA | Walgreens | 0363-0730-41 | 1 TUBE, WITH APPLICATOR in 1 CARTON (0363-0730-41) / 45 g in 1 TUBE, WITH APPLICATOR | 2000-12-01 |
| P And L | MICONAZOLE 7 | miconazole nitrate | CREAM;VAGINAL | 074164 | ANDA | Major Pharmaceuticals | 0904-7734-45 | 1 TUBE, WITH APPLICATOR in 1 CARTON (0904-7734-45) / 45 g in 1 TUBE, WITH APPLICATOR | 2009-04-21 |
| P And L | MICONAZOLE 7 | miconazole nitrate | CREAM;VAGINAL | 074164 | ANDA | EQUATE (Wal-Mart Stores, Inc.) (see also WAL-MART INC) | 49035-347-07 | 7 TUBE, WITH APPLICATOR in 1 CARTON (49035-347-07) / 45 g in 1 TUBE, WITH APPLICATOR | 2020-05-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: MICONAZOLE 7%
Introduction
Miconazole is a widely used antifungal agent, particularly in topical formulations such as creams, ointments, and powders. The “Miconazole 7%” formulation indicates a concentrated topical preparation, often used in dermatological and fungal infection treatments. As global demand for effective antifungal treatments persists, identifying reputable suppliers for Miconazole 7% becomes crucial for pharmaceutical companies, distributors, and healthcare providers seeking reliable sourcing options. This article provides a comprehensive overview of key suppliers, their market positioning, regulatory considerations, and strategic insights into sourcing Miconazole 7%.
Overview of Miconazole 7%
Miconazole functions as an imidazole antifungal agent, disrupting fungal cell membrane synthesis by inhibiting ergosterol production. The 7% topical formulation offers a potent antifungal effect, suitable for dermatophyte infections and other fungal skin conditions. The formulation’s high concentration necessitates strict quality standards, manufacturing compliance, and supply chain integrity.
Global Supply Landscape
The global Miconazole market is characterized by a mix of large multinational pharmaceutical companies, specialized generics manufacturers, and regional suppliers. Demand centers include North America, Europe, Asia-Pacific, and Latin America, driven by the prevalence of fungal infections and expanding healthcare infrastructure.
Key Suppliers of Miconazole 7%
1. Dr. Reddy’s Laboratories
A prominent Indian pharmaceutical company with a robust portfolio of topical antifungal formulations, Dr. Reddy’s supplies Miconazole in various strengths, including 7%. The company emphasizes strict adherence to GMP standards, ensuring high-quality APIs and finished products. Their extensive distribution network facilitates global reach, especially in emerging markets.
2. Mylan (Viatris Inc.)
Mylan, now part of Viatris, offers a comprehensive range of antifungal products, including Miconazole topical formulations. They focus on compliance with international regulatory standards such as US FDA, EMA, and WHO approvals, making them a reliable partner for large-scale procurement. Their manufacturing facilities are located in the US, India, and Europe, contributing to diversified supply channels.
3. Teva Pharmaceuticals
Known for generics production, Teva supplies Miconazole-based topical products across multiple markets. Their emphasis on quality control and regulatory compliance positions them as a trusted supplier, especially in North America and Europe. They maintain strategic manufacturing partnerships and possess a broad distribution network.
4. Cipla Limited
As a leading Indian pharmaceutical manufacturer, Cipla offers topical antifungal agents, including Miconazole 7%. Their reputation for cost-effective, high-quality formulations makes them a popular choice in developing markets. Cipla’s global presence is strengthened by their robust export operations and adherence to strict quality standards.
5. GSK (GlaxoSmithKline)
While primarily known for prescription medications, GSK produces Miconazole products, often in combination formulations. They operate in multiple regulatory jurisdictions, reinforcing their ability to supply the drug internationally. Their focus on innovative delivery mechanisms and high-quality standards enhances their reputation as suppliers of Miconazole.
Regional and Niche Suppliers
Apart from major global players, regional manufacturers in China, South Korea, and Brazil are significant sources of Miconazole. These suppliers often support local markets with lower-cost formulations, but their suitability depends on regulatory validation, quality assurance, and supply chain reliability.
Regulatory and Quality Considerations
Sourcing Miconazole 7% from reputable suppliers requires meticulous review of compliance with Good Manufacturing Practices (GMP), ISO certifications, and regulatory approvals (e.g., FDA, EMA, WHO). Suppliers should provide Certificates of Analysis (CoA), stability data, and licensing documentation to ensure product efficacy and safety. Contract manufacturing agreements should detail specifications, quality standards, and traceability measures.
Supply Chain and Risk Management
Given the criticality of antifungal medications, it is essential to identify suppliers with resilient supply chains, contingency plans, and capacity for scale-up. Disruptions due to geopolitical issues, raw material shortages, or regulatory changes necessitate diversified sourcing strategies. Establishing early communication channels and engaging with multiple suppliers mitigates risks and ensures continuous supply.
Market Trends Impacting Supplier Selection
The growing prevalence of fungal infections, driven by immunocompromised populations and aging demographics, is expanding the demand for Miconazole formulations. Additionally, regulatory shifts towards stricter approval processes and quality standards influence supplier evaluations. Emphasizing suppliers with proven compliance and ability to adapt to evolving regulatory landscapes will benefit long-term procurement strategies.
Conclusion
Reliable sourcing of Miconazole 7% hinges on partnering with established manufacturers who demonstrate robust quality systems, regulatory compliance, and supply chain resilience. No single supplier dominates the market; instead, businesses should cultivate diversified supplier relationships tailored to regional needs and regulatory requirements. Ensuring product quality, transparent documentation, and adherence to international standards will safeguard operations and patient safety in the distribution of this critical antifungal agent.
Key Takeaways
- Major global suppliers include Dr. Reddy’s Laboratories, Mylan (Viatris), Teva Pharmaceuticals, Cipla, and GSK.
- Regulatory compliance and quality assurance are paramount when sourcing Miconazole 7%.
- A diversified supplier portfolio mitigates supply chain risks and supports scalability.
- Regional manufacturers can offer cost advantages but require rigorous vetting for quality and regulatory adherence.
- Staying abreast of market trends and regulatory updates enhances procurement strategies for antifungal products.
FAQs
1. How do I verify the quality of Miconazole 7% from suppliers?
Always request Certificates of Analysis (CoA), batch traceability, regulatory approvals, and GMP certification. Conduct audits or third-party testing when feasible.
2. What regulatory considerations should be addressed when importing Miconazole 7%?
Ensure compliance with local drug regulations, import licenses, and validate that suppliers have necessary approvals (FDA, EMA, etc.).
3. Can regional manufacturers meet global quality standards for Miconazole 7%?
While some regional manufacturers adhere to international standards, due diligence is essential. Select suppliers with ISO certifications and GMP compliance.
4. What supply chain risks are associated with sourcing Miconazole 7%?
Risks include geopolitical disruptions, raw material shortages, manufacturing delays, and regulatory changes. Diversification and proactive risk management mitigate these risks.
5. Are there emerging suppliers or markets for Miconazole 7%?
Yes, emerging markets in Asia, Latin America, and Africa are expanding their local manufacturing capacities. Collaboration with reputed regional suppliers can optimize supply and reduce costs.
Sources
[1] Industry reports on antifungal drug markets.
[2] Company websites and product catalogs (Dr. Reddy’s, Mylan, Teva, Cipla, GSK).
[3] Regulatory agency guidelines (FDA, EMA, WHO).
[4] Market analyses and supply chain reviews.
More… ↓
